Abstract: Embodiments of the disclosure include methods and compositions related to treating or reducing the severity or delaying the onset of one or more cardiac conditions in a mammal. In particular embodiments, the compositions concern Park2 and its use for a cardiac medical condition. In specific cases, effective amounts of Park2 polynucleotide(s) and/or Park2 polypeptide(s) are provided to an individual in need thereof, including for heart failure, for example. The administration may be locally to the heart, for example.
Abstract: MiniVectors and compositions containing MiniVectors that target genes implicated in IPF selected from CDH11, STAT3, STAT6, FoxM1, MDM2, TGF?, SMAD, PDGFA, or TLR4 and/or increase intracellular levels of reduced glutathione, relaxin, and p53, are provided, along with uses in the treatment of idiopathic pulmonary fibrosis.
Type:
Application
Filed:
September 7, 2022
Publication date:
March 28, 2024
Applicants:
Twister Biotech, Inc, Baylor College of Medicine
Inventors:
E. Lynn ZECHIEDRICH, Lirio Milenka AREVALO-SOLIZ, Daniel James CATANESE, JR., Jonathan Marcus FOGG, Christopher E. COKER
Abstract: Methods and compositions used to identify and characterize novel rhodopsin domains, which are kalium (potassium)-conducting channelrhodopsins. The rhodopsin domain of these kalium (potassium)-conducting channelrhodopsins have been cloned, optimized and expressed in mammalian systems and thus may be used in, among others, optogenetic applications and as therapeutic agents for electrically active cell mediated disorders.
Type:
Application
Filed:
September 12, 2023
Publication date:
March 28, 2024
Applicants:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, BAYLOR COLLEGE OF MEDICINE
Inventors:
John Lee SPUDICH, Elena G. GOVORUNOVA, Oleg A. SINESHCHEKOV, Mingshan XUE
Abstract: MiniVectors and compositions containing MiniVectors that are ultrapure, and methods of making and using ultrapure MiniVectors for gene therapy uses, including long term repeated gene therapy uses.
Type:
Application
Filed:
September 8, 2022
Publication date:
March 21, 2024
Applicants:
BAYLOR COLLEGE OF MEDICINE, BAYLOR COLLEGE OF MEDICINE
Inventors:
E. Lynn ZECHIEDRICH, Jonathan Marcus FOGG, Lirio Milenka AREVALO-SOLIZ, Daniel James CATANESE, Christopher E. COKER
Abstract: Embodiments of the disclosure concern methods of identifying whether or not antigens from a particular pathogen are immunogenic, including the order of their immunogenicity. Other embodiments concern correlations between attributes of T cells and their clinical efficacy, such as mathematical representations thereof.
Type:
Grant
Filed:
September 21, 2021
Date of Patent:
March 19, 2024
Assignee:
Baylor College of Medicine
Inventors:
Ann Marie Leen, Pailbel Aguayo-Hiraldo, Ifigeneia Tzannou, Juan F. Vera Valdes
Abstract: Embodiments of the disclosure concern systems, methods, and/or compositions for cultivation of mammalian viruses, including at least human noroviruses and sapoviruses within the Caliciviridae family of viruses. The ex vivo culture systems include intestinal enteroids in combination with bile or a functionally active fraction or component thereof. In specific embodiments, the culture system is utilized to test inactivation compounds for therapeutic or environmental efficacy and to test contaminated comestibles and/or environmental entities for determination of the presence of infectious virus. Furthermore, antiviral compositions may be tested using systems of the disclosure, including drugs, small molecule inhibitors, and biologics such as neutralizing monoclonal antibodies.
Type:
Grant
Filed:
July 8, 2022
Date of Patent:
March 5, 2024
Assignee:
Baylor College of Medicine
Inventors:
Mary K. Estes, David Graham, Robert Legare Atmar, Sue Ellen Crawford, Khalil Ettayebi, Kosuke Murakami
Abstract: Small molecules acting through the ligand binding domain of nuclear receptor TLX (NR2E1) are disclosed, as well as the use thereof for promoting neurogenesis and treating disorders associated with nuclear receptor TLX, including neurological disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula II as described herein, and pharmaceutically acceptable salts or isomers thereof.
Abstract: Systems and methods for a multi-primary color system for display. A multi-primary color system increases the number of primary colors available in a color system and color system equipment. Increasing the number of primary colors reduces metameric errors from viewer to viewer. One embodiment of the multi-primary color system includes Red, Green, Blue, Cyan, Yellow, and Magenta primaries. The systems of the present invention maintain compatibility with existing color systems and equipment and provide systems for backwards compatibility with older color systems.
Type:
Application
Filed:
October 4, 2023
Publication date:
February 22, 2024
Applicant:
Baylor University
Inventors:
Mitchell J. Bogdanowicz, Gary B. Mandle
Abstract: Systems and methods for a six-primary color system for display. A six-primary color system increases the number of primary colors available in a color system and color system equipment. Increasing the number of primary colors reduces metameric errors from viewer to viewer. The six-primary color system includes Red, Green, Blue, Cyan, Yellow, and Magenta primaries. The systems of the present invention maintain compatibility with existing color systems and equipment and provide systems for backwards compatibility with older color systems.
Abstract: Systems and methods for displaying super saturated color. Image data for display on a display or viewing device with a potential white luminance in a standard system with a maximum luminance is processed such that colors near the white point are reduced to a limited luminance. As the chroma of the displayed color is increased, a luminance attenuation is decreased. The scaling of the reduction is operable to be a linear function, a non-linear function, or any other function.
Type:
Application
Filed:
October 26, 2023
Publication date:
February 15, 2024
Applicant:
Baylor University
Inventors:
Mitchell J. Bogdanowicz, James M. DeFilippis, Corey P. Carbonara, Michael F. Korpi, Gary B. Mandle
Abstract: Disclosed is a handheld laser probe for laser thermal conjunctivoplasty, the handheld laser comprising: a forceps; and a line focused laser light source coupled to the forceps, wherein the forceps are configured to grasp a conjunctival fold and hold the fold in a light beam of the line focused laser, and wherein the line focused laser beam is configured to uniformly heat the conjunctival fold held in the forceps. Disclosed are systems for laser thermal conjunctivoplasty including the handheld laser. Disclosed are methods of conjunctivoplasty using the handheld laser probe.
Type:
Grant
Filed:
February 27, 2018
Date of Patent:
February 13, 2024
Assignees:
OREGON HEALTH & SCIENCE UNIVERSITY, BAYLOR COLLEGE OF MEDICINE
Inventors:
David Huang, Gangjun Liu, Jianlong Yang, Stephen Pflugfelder
Abstract: The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor; and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.
Abstract: Systems and methods for a multi-primary color system for display. A multi-primary color system increases the number of primary colors available in a color system and color system equipment. Increasing the number of primary colors reduces metameric errors from viewer to viewer. One embodiment of the multi-primary color system includes Red, Green, Blue, Cyan, Yellow, and Magenta primaries. The systems of the present invention maintain compatibility with existing color systems and equipment and provide systems for backwards compatibility with older color systems.
Type:
Grant
Filed:
October 19, 2022
Date of Patent:
February 6, 2024
Assignee:
BAYLOR UNIVERSITY
Inventors:
Gary B. Mandle, James M. DeFilippis, Mitchell J. Bogdanowicz, Corey P. Carbonara, Michael F. Korpi
Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
Abstract: The present disclosure provides a system and method for using widely available ultrasound imaging to overcome the limitations of imaging guidewires and other small objects that may be subwavelength in size relative to an ultrasound wavelength. The system and method can reduce the use of X-rays and exposure to the dangerous effects of radiation and avoids the expense of MRI technology. The subwavelength object, such as a guidewire, can be detected using several methods and associated systems described herein, including the object changing positions at a frequency that creates a brighter ultrasound image of the object as the object progresses across a scanned region of the ultrasound detector. In some embodiments, the movement of the small object causes a different speckle signature than the object itself would otherwise generate. Analysis of changes in speckle patterns due to progressive movement of an object can yield a detectable object.
Type:
Grant
Filed:
May 18, 2021
Date of Patent:
January 30, 2024
Assignees:
BAYLOR UNIVERSITY, SCOTT & WHITE HEALTHCARE
Inventors:
Linda J. Olafsen, Keith E. Schubert, Jeffrey S. Olafsen, Samantha Dayawansa, Jason H. Huang
Abstract: Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13R?2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13R?2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).
Type:
Application
Filed:
May 1, 2023
Publication date:
January 25, 2024
Applicants:
The University of Chicago, Baylor College of Medicine
Inventors:
Irina V. BALYASNIKOVA, Maciej S LESNIAK, Stephen M.G. GOTTSCHALK
Abstract: Systems and methods for a multi-primary color system for display. A multi-primary color system increases the number of primary colors available in a color system and color system equipment. Increasing the number of primary colors reduces metameric errors from viewer to viewer. One embodiment of the multi-primary color system includes Red, Green, Blue, Cyan, Yellow, and Magenta primaries. The systems of the present invention maintain compatibility with existing color systems and equipment and provide systems for backwards compatibility with older color systems.
Type:
Application
Filed:
August 4, 2023
Publication date:
January 25, 2024
Applicant:
Baylor University
Inventors:
James M. DeFilippis, Mitchell J. Bogdanowicz, Corey P. Carbonara, Michael F. Korpi, Gary B. Mandle
Abstract: Systems and corresponding methods for an end-expandable optical fiber bundle are described herein. In one aspect, an endoscope can include a plurality of optical fibers each having a proximal end and a distal end; at least one camera coupled to the proximal ends of the plurality of optical fibers; and a sleeve enveloping the plurality of optical fibers proximate to the distal ends and repositionable along the length of the plurality of optical fibers, such that the sleeve is configured to control an angle of bend for each of the plurality of optical fibers as the optical fibers advance past the sleeve.
Type:
Application
Filed:
August 25, 2021
Publication date:
January 25, 2024
Applicants:
Baylor College of Medicine, William Marsh Rice University
Inventors:
Elena Petrova, Sharmila Anandasabapathy, Rebecca Richards-Kortum
Abstract: Provided herein are compositions and methods for the synthesis, amplification, and in vitro transcription of full-length cDNA, or cDNA fragments. Methods are provided for reverse transcription of RNA and amplification for in vitro transcription. Further provided are method for loading of dendritic cells with the RNA and homologous lysate for immune stimulation.
Abstract: The described process synthesizes a halide-free single-site borane compound product tris(ortho-carboranyl)borane, or BoCb3. BoCb3 has Lewis superacid properties. The compounds, BoCb3, are thermally stable, and not reactive towards oxygen, but are sensitive to water. The characteristic high fluoride ion affinity is further translated to the catalytic C—F bond activation reactions of the unactivated alkyl fluorides towards the reduction and C—C bond forming reactions with silanes, and Fridel-Crafts type reactions with arenes. The potential of the synthesized Lewis acid as a catalysis is anticipated.